| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02038699 | Advanced Glioblastoma|Advanced Colorectal Cancer|Advanced Triple-negative Breast Cancer|Advanced Non-small Cell Lung Cancer | Drug: ONC201 | Oncoceutics, Inc. | Phase 1|Phase 2 | null | 2015-12-18 |
| NCT02250781 | Solid Tumors | Drug: Oral ONC201 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey | Phase 1 | 2015-01-01 | 2017-02-01 |
| NCT02324621 | Unspecified Adult Solid Tumor | Drug: Oral ONC201|Other: pharmacological study|Other: laboratory biomarker analysis | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Oncoceutics, Inc. | Phase 1 | 2015-02-01 | 2017-01-19 |
| NCT02863991 | Multiple Myeloma | Drug: ONC201 | Oncoceutics, Inc. | Phase 1|Phase 2 | 2016-01-01 | 2017-03-20 |
| NCT03034200 | Recurrent Neuroendocrine Tumor|Metastatic Neuroendocrine Tumor | Drug: ONC201 | Peter Anderson|Case Comprehensive Cancer Center | Phase 2 | 2017-02-01 | 2017-01-25 |
| NCT02420795 | Lymphoma | Drug: ONC201|Behavioral: Phone Call | M.D. Anderson Cancer Center|Oncoceutics, Inc. | Phase 1|Phase 2 | 2015-11-03 | 2017-01-23 |
| NCT02609230 | Advanced Solid Tumors|Multiple Myeloma | Drug: ONC-201 | Fox Chase Cancer Center | Phase 1 | 2015-11-01 | 2017-01-25 |
| NCT02392572 | Leukemia | Drug: ONC201 | M.D. Anderson Cancer Center|Oncoceutics, Inc. | Phase 1|Phase 2 | 2015-11-01 | 2016-12-27 |
| NCT02525692 | Recurrent Glioblastoma | Drug: ONC201 | Oncoceutics, Inc. | Phase 2 | 2016-01-01 | 2017-03-19 |
| NCT02190721 | Solid Tumors | Drug: tbo-filgrastim | Teva Pharmaceutical Industries | Phase 2 | 2015-05-01 | 2017-03-13 |
